DE60303131D1 - Synergistische wechselwirkung von abacavir und alovudin - Google Patents

Synergistische wechselwirkung von abacavir und alovudin

Info

Publication number
DE60303131D1
DE60303131D1 DE60303131T DE60303131T DE60303131D1 DE 60303131 D1 DE60303131 D1 DE 60303131D1 DE 60303131 T DE60303131 T DE 60303131T DE 60303131 T DE60303131 T DE 60303131T DE 60303131 D1 DE60303131 D1 DE 60303131D1
Authority
DE
Germany
Prior art keywords
abacavir
alovudin
synergistic interaction
alovudine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60303131T
Other languages
English (en)
Other versions
DE60303131T2 (de
Inventor
Goeran Mardh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0202022A external-priority patent/SE0202022D0/xx
Application filed by Medivir AB filed Critical Medivir AB
Publication of DE60303131D1 publication Critical patent/DE60303131D1/de
Application granted granted Critical
Publication of DE60303131T2 publication Critical patent/DE60303131T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
DE60303131T 2002-06-27 2003-06-24 Synergistische wechselwirkung von abacavir und alovudin Expired - Fee Related DE60303131T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0202022A SE0202022D0 (sv) 2002-06-27 2002-06-27 Synergistic interaction of abacavir and alovudine
SE0202022 2002-06-27
EP02024744 2002-11-06
EP02024744 2002-11-06
PCT/SE2003/001100 WO2004002433A1 (en) 2002-06-27 2003-06-24 Synergistic interaction of abacavir and alovudine

Publications (2)

Publication Number Publication Date
DE60303131D1 true DE60303131D1 (de) 2006-03-30
DE60303131T2 DE60303131T2 (de) 2006-07-20

Family

ID=30001852

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60303131T Expired - Fee Related DE60303131T2 (de) 2002-06-27 2003-06-24 Synergistische wechselwirkung von abacavir und alovudin

Country Status (19)

Country Link
US (1) US20060084627A1 (de)
EP (1) EP1536800B1 (de)
JP (1) JP2005533870A (de)
KR (1) KR20050013628A (de)
CN (1) CN1302779C (de)
AT (1) ATE314851T1 (de)
AU (1) AU2003239088B2 (de)
BR (1) BR0311141A (de)
CA (1) CA2481890A1 (de)
DE (1) DE60303131T2 (de)
ES (1) ES2254941T3 (de)
HK (1) HK1079981B (de)
IL (1) IL164921A0 (de)
MX (1) MXPA04012754A (de)
NO (1) NO20050445L (de)
NZ (1) NZ535817A (de)
PL (1) PL373758A1 (de)
RU (1) RU2320347C2 (de)
WO (1) WO2004002433A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610797A1 (de) * 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antivirale kombination von nevirapin und einer weiteren antiretroviralen verbindung
GB0608876D0 (en) 2006-05-05 2006-06-14 Medivir Ab Combination therapy
KR101830715B1 (ko) 2010-01-27 2018-04-04 비이브 헬쓰케어 컴퍼니 Hiv 감염을 치료하기 위한 약학적 조합물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
GB8719877D0 (en) * 1987-08-22 1987-09-30 Wellcome Found Antiviral compounds
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
CN1257912C (zh) * 1998-08-10 2006-05-31 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β－L－2′－脱氧－核苷
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
ATE324894T1 (de) * 1999-01-22 2006-06-15 Univ Emory Beta-d-2', 3' -didehydro-2', 3' -didesoxy-5- fluorocytidin für die verwendung in der behandlung von hiv infektionen
US6514979B1 (en) * 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
CA2411354A1 (en) * 2000-06-02 2001-12-13 Smithkline Beecham Corporation Methods of treating viral diseases with il-18 and il-18 combinations

Also Published As

Publication number Publication date
ATE314851T1 (de) 2006-02-15
BR0311141A (pt) 2005-06-07
NO20050445L (no) 2005-01-26
PL373758A1 (en) 2005-09-05
EP1536800B1 (de) 2006-01-04
ES2254941T3 (es) 2006-06-16
WO2004002433A8 (en) 2004-05-06
EP1536800A1 (de) 2005-06-08
MXPA04012754A (es) 2005-03-23
NZ535817A (en) 2006-11-30
HK1079981A1 (en) 2006-04-21
US20060084627A1 (en) 2006-04-20
AU2003239088B2 (en) 2006-11-02
CA2481890A1 (en) 2004-01-08
RU2320347C2 (ru) 2008-03-27
CN1665509A (zh) 2005-09-07
HK1079981B (zh) 2007-10-12
IL164921A0 (en) 2005-12-18
DE60303131T2 (de) 2006-07-20
CN1302779C (zh) 2007-03-07
JP2005533870A (ja) 2005-11-10
WO2004002433A1 (en) 2004-01-08
RU2005101874A (ru) 2005-06-27
AU2003239088A1 (en) 2004-01-19
KR20050013628A (ko) 2005-02-04

Similar Documents

Publication Publication Date Title
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
AR032293A1 (es) Estuche farmaceutico
DE60312523D1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
ATE292453T1 (de) Antivirale arznei
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
AR023597A1 (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion
HK1068606A1 (en) Novel aminobenzoephenones
ATE314851T1 (de) Synergistische wechselwirkung von abacavir und alovudin
HUP0204208A2 (hu) Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény
EP1273301A3 (de) Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung bieten
AU2003281468A1 (en) P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient
TR200102930T2 (tr) Ruhsal bozuklukların tedavisinde yararlı olan ilaçların üretiminde osanetat kullanımı
ATE261732T1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
DE69717279D1 (de) Mittel gegen malaria und babesia und diese enthaltende pfarmazeutische zubereitungen
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
DE50005282D1 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
AU2002225097A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
DE50307169D1 (de) ORALE VAKZINIERUNG MIT DEM TUMOR-ANTIGEN-MIMOTOP Gln-Met-Trp-Ala-Pro-Gln-Trp-Gly-Pro-Asp
ATE382342T1 (de) Pomolsäure zur behandlung von mehrfachresistenten tumoren
UA34406A (uk) Засіб для лікування розсіяного склерозу, спосіб лікування з його використанням та фармацевтична упаковка
ECSP993244A (es) Cicloheptenos sustituidos, procedimiento para su preparacion y su uso como medicamento

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee